CPH Cipher Pharmaceuticals Inc
- 8.390
- 0.0000.00%
Cipher Pharmaceuticals Inc News
Press Release: Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders Canada NewsWire MISSISSAUGA, ON, June 14, 2024 MISSISSAUGA, ON, June 14, 2024 /CNW/ - Cipher Pharmaceuticals I
Earnings Call Summary | Cipher Pharmaceuticals Inc(CPHRF.US) Q1 2024 Earnings Conference
The following is a summary of the Cipher Pharmaceuticals Inc. (CPHRF) Q1 2024 Earnings Call Transcript:Financial Performance:Cipher reported a total net revenue for Q1 2024 of $5.9 million, a 20% incr
Stocks in Play: Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mississauga, Ontario--(Newsfile Corp. - April 3, 2024) - Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which wil
Cipher Pharmaceuticals Q4 Profit Falls 61% on Charges
Cipher Pharmaceuticals (CPH.TO) on Thursday said its fourth-quarter profit fell 61% on charges. The company said it earned US$7.7 million, or US$0.32 per share, in the period, down from a profit of US
Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call
Cipher Pharmaceuticals Inc. Raised to Buy From Speculative Buy by Citigroup
Cipher Pharmaceuticals Inc. Raised to Buy From Speculative Buy by Citigroup
Cipher Pharmaceuticals Upgraded to Buy at Stifel GMP; Price Target Raised to C$8.00
Stifel GMP on Wednesday upgraded its rating on the shares of Cipher Pharmaceuticals (CPH.TO) to buy from speculative buy and raised its price target to C$8.00 from C$4.75 for the specialty pharmaceuti
Cipher Pharmaceuticals Announces the Commencement of OTCQX Trading
OTC Markets Group Welcomes Cipher Pharmaceuticals Inc. to OTCQX
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Cipher Pharmaceuticals Inc. (TSX:CPH,
Cipher Pharmaceuticals Announces Change of Auditor
Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call
Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of Its Substantial Issuer Bid
Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars
Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call
Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Mississauga, Ontario--(Newsfile Corp. - April 18, 2023) - Cipher Pharmaceuticals (TSX: CPH), a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage produ
Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Sees Significant Growth in Short Interest
Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF – Get Rating) (TSE:CPH) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,000 sh
Short Interest in Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Decreases By 33.3%
Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF – Get Rating) (TSE:CPH) was the target of a large decline in short interest in December. As of December 30th, there was short interest totalling 1,600 share
